Broadwood Partners, L.P. Purchases 36,532 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $15.49 per share, with a total value of $565,880.68. Following the purchase, the insider now owns 11,289,437 shares in the company, valued at $174,873,379.13. The trade was a 0.32 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The stock was acquired at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.46 per share, with a total value of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.33 per share, with a total value of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Stock Performance

Shares of STAA opened at $15.35 on Friday. The company has a 50-day simple moving average of $23.37 and a 200-day simple moving average of $28.97. The firm has a market capitalization of $756.45 million, a P/E ratio of 34.89 and a beta of 0.62. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $52.68.

Analysts Set New Price Targets

STAA has been the subject of several analyst reports. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $45.00 to $17.00 in a research note on Wednesday. Piper Sandler cut their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday. William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, StockNews.com lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $26.86.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI acquired a new position in shares of STAAR Surgical during the third quarter valued at about $37,000. Quarry LP acquired a new position in shares of STAAR Surgical during the third quarter valued at about $50,000. Quest Partners LLC acquired a new position in shares of STAAR Surgical during the third quarter valued at about $128,000. Van ECK Associates Corp raised its position in shares of STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after buying an additional 393 shares during the last quarter. Finally, nVerses Capital LLC increased its stake in STAAR Surgical by 78.3% in the third quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after acquiring an additional 1,800 shares during the period. Institutional investors and hedge funds own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.